Greffex scientists create first H7N9 avian influenza vaccine
In about one month after the H7N9 avian influenza virus was characterized, Aurora, Colorado vaccine manufacturer, Greffex has created a H7N9 avian influenza vaccine using its proprietary GREVAXTM technology, according to a press release today.
“We believe the world needs a ‘plug-and-play’TM method of creating vaccines,” says Greffex Chief Scientific Officer Dr. Uwe D. Staerz. “Speed as well as flexibility is needed for vaccine design to combat emerged infectious threats. We had already shown with an Anthrax vaccine that we can create ANY vaccine within one month.”
The GREVAXTM vaccine platform integrates short development times, with large payloads, carrying the H7N9 avian influenza hemagglutinin and neuramidase genes, and high levels of plasticity. It focuses the potent immunogenicity of adenovirus-based engineered vaccines to vaccine antigens, as it is fully deleted of adenoviral genes and devoid of helper viruses.
“We originally created the GREVAX(TM) system for H1N1 swine influenza, and now have a Dengue vaccine, an Anthrax vaccine, an Ebola vaccine, and avian influenza vaccines, and we have overcome major production and manufacturing obstacles,” says John R. Price, President and Chief Executive Officer of Greffex. “And we are working on a universal influenza vaccine, the ‘holy grail’ of vaccine science.”
For more infectious disease news and information, visit and “like” the Infectious Disease News Facebook page